Genzyme Biosurgery's Focal Acquisition Boosts Biopolymer Presence
This article was originally published in The Gray Sheet
Executive Summary
Genzyme Biosurgery's April 26 announcement that it will acquire the 78% of Focal, Inc. it does not already own for about $10 mil. in stock builds on an existing U.S. marketing agreement covering FocalSeal-L lung surgery sealant and further bolsters the company's presence in the biopolymers market.